PT2849798T - Composições de complexo quelato de oligonucleótidos-polipéptido e métodos - Google Patents

Composições de complexo quelato de oligonucleótidos-polipéptido e métodos

Info

Publication number
PT2849798T
PT2849798T PT137916185T PT13791618T PT2849798T PT 2849798 T PT2849798 T PT 2849798T PT 137916185 T PT137916185 T PT 137916185T PT 13791618 T PT13791618 T PT 13791618T PT 2849798 T PT2849798 T PT 2849798T
Authority
PT
Portugal
Prior art keywords
methods
chelate complex
polypeptide compositions
oligonucleotide chelate
oligonucleotide
Prior art date
Application number
PT137916185T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2849798(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of PT2849798T publication Critical patent/PT2849798T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
PT137916185T 2012-05-18 2013-05-17 Composições de complexo quelato de oligonucleótidos-polipéptido e métodos PT2849798T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30

Publications (1)

Publication Number Publication Date
PT2849798T true PT2849798T (pt) 2021-05-18

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137916185T PT2849798T (pt) 2012-05-18 2013-05-17 Composições de complexo quelato de oligonucleótidos-polipéptido e métodos

Country Status (34)

Country Link
US (1) US9492506B2 (OSRAM)
EP (1) EP2849798B1 (OSRAM)
JP (1) JP2015517504A (OSRAM)
KR (1) KR102068109B1 (OSRAM)
CN (1) CN104349793B (OSRAM)
AU (1) AU2013262416B2 (OSRAM)
BR (1) BR112014028654A2 (OSRAM)
CA (1) CA2873529C (OSRAM)
CL (1) CL2014003134A1 (OSRAM)
CO (1) CO7131387A2 (OSRAM)
CR (1) CR20140527A (OSRAM)
CY (1) CY1124345T1 (OSRAM)
DK (1) DK2849798T3 (OSRAM)
DO (1) DOP2014000264A (OSRAM)
EA (1) EA035967B1 (OSRAM)
EC (1) ECSP14027694A (OSRAM)
ES (1) ES2873844T3 (OSRAM)
HR (1) HRP20210840T1 (OSRAM)
HU (1) HUE054875T2 (OSRAM)
IL (1) IL235548B (OSRAM)
LT (1) LT2849798T (OSRAM)
MX (1) MX346239B (OSRAM)
MY (1) MY168778A (OSRAM)
NZ (1) NZ703095A (OSRAM)
PH (1) PH12014502551B1 (OSRAM)
PL (1) PL2849798T3 (OSRAM)
PT (1) PT2849798T (OSRAM)
RS (1) RS62030B1 (OSRAM)
SG (1) SG11201407599SA (OSRAM)
SI (1) SI2849798T1 (OSRAM)
SM (1) SMT202100319T1 (OSRAM)
TW (1) TWI635864B (OSRAM)
WO (1) WO2013170386A1 (OSRAM)
ZA (1) ZA201408674B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2158316T3 (en) 2007-05-11 2015-07-20 Adynxx Inc Gene expression and pain
RU2668136C2 (ru) 2012-05-10 2018-09-26 Эйдинкс, Инк. Композиции для доставки активных ингредиентов
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections
PT3166615T (pt) * 2014-07-10 2023-11-13 Replicor Inc Polímeros de ácidos nucleicos fosforotioados quelados para utilização em combinação com um inibidor da polimerase de hbv para o tratamento de infeções pelo vírus da hepatite b e hepatite d
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
MA53674A (fr) * 2018-11-08 2021-07-28 Aligos Therapeutics Inc Polymères oligonucléotidiques inhibant le transport de l'antigène s et procédés
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
WO2004024919A1 (en) * 2002-09-13 2004-03-25 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2004076474A2 (en) 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
EP1802643A1 (en) * 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
WO2007036016A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2008334948B2 (en) * 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010138806A2 (en) * 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
US8598334B2 (en) * 2009-10-16 2013-12-03 Glaxo Group Limited HBV antisense inhibitors
SI2605794T1 (sl) * 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi
WO2014032176A1 (en) 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
TWI635864B (zh) 2018-09-21
KR20150013309A (ko) 2015-02-04
CA2873529C (en) 2020-08-18
HUE054875T2 (hu) 2021-10-28
ECSP14027694A (es) 2015-12-31
DK2849798T3 (da) 2021-05-31
JP2015517504A (ja) 2015-06-22
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
AU2013262416B2 (en) 2017-05-11
EP2849798A4 (en) 2016-03-09
CN104349793A (zh) 2015-02-11
EP2849798A1 (en) 2015-03-25
WO2013170386A1 (en) 2013-11-21
CN104349793B (zh) 2017-11-10
CL2014003134A1 (es) 2015-02-13
EA201401278A1 (ru) 2015-04-30
LT2849798T (lt) 2021-08-10
AU2013262416A1 (en) 2014-12-18
US9492506B2 (en) 2016-11-15
CY1124345T1 (el) 2022-07-22
ES2873844T3 (es) 2021-11-04
SG11201407599SA (en) 2014-12-30
HK1204279A1 (en) 2015-11-13
HRP20210840T1 (hr) 2021-08-06
MY168778A (en) 2018-12-04
CO7131387A2 (es) 2014-12-01
ZA201408674B (en) 2016-01-27
MX2014014021A (es) 2015-02-10
SI2849798T1 (sl) 2021-08-31
DOP2014000264A (es) 2015-01-31
CR20140527A (es) 2014-12-15
CA2873529A1 (en) 2013-11-21
PH12014502551B1 (en) 2019-10-11
US20130309201A1 (en) 2013-11-21
MX346239B (es) 2017-03-13
EP2849798B1 (en) 2021-04-07
NZ703095A (en) 2016-07-29
EA035967B1 (ru) 2020-09-07
PH12014502551A1 (en) 2015-01-21
IL235548B (en) 2019-07-31
KR102068109B1 (ko) 2020-01-21
TW201408308A (zh) 2014-03-01
PL2849798T3 (pl) 2021-10-18
SMT202100319T1 (it) 2021-09-14
RS62030B1 (sr) 2021-07-30

Similar Documents

Publication Publication Date Title
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL233649B (en) Preparations derived from chitosan
EP2852602A4 (en) COMPOSITIONS AND METHODS FOR CONJUGATING OLIGONUCLEOTIDES
ZA201408082B (en) Oligonucleotide chelate complex methods
ZA201408674B (en) Oligonucleotide chelate complex-polypeptide compositions and methods
GB2511197B (en) Compositions
GB201315350D0 (en) Methods and compositions
GB201210800D0 (en) Compositions
GB201209244D0 (en) Compositions
GB201315347D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB201201287D0 (en) Compositions
GB201220068D0 (en) Compositions
GB201318407D0 (en) Compositions
GB201219980D0 (en) Compositions
GB201219973D0 (en) Compositions
TWI561248B (en) Peracid-generating compositions
GB201116340D0 (en) Compositions and methods
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions
GB201218959D0 (en) Compositions
GB201209189D0 (en) Compositions
GB201204103D0 (en) Compositions
GB201204102D0 (en) Compositions